GLP-1-based therapy for diabetes: what you do not know can hurt you

Diabetes Care. 2010 Feb;33(2):453-5. doi: 10.2337/dc09-1902.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Clinical Trials as Topic
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Glucagon-Like Peptide 1 / adverse effects
  • Glucagon-Like Peptide 1 / therapeutic use*
  • Humans
  • Hypoglycemic Agents / adverse effects
  • Hypoglycemic Agents / therapeutic use
  • Obesity / complications
  • PPAR gamma / agonists
  • Pancreatic Neoplasms / epidemiology
  • Risk Assessment
  • Safety

Substances

  • Hypoglycemic Agents
  • PPAR gamma
  • Glucagon-Like Peptide 1